Search Result

Results for "

Pulmonary hypertension

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (9) Adrenergic Receptor (1) Akt (3) Aldehyde Dehydrogenase (ALDH) (1) AMPK (1) Angiotensin Receptor (3) Angiotensin-converting Enzyme (ACE) (3) Antibiotic (2) Apelin Receptor (APJ) (4) Apoptosis (10) Autophagy (3) Bacterial (8) Bcl-2 Family (1) c-Fms (1) c-Kit (1) Caspase (3) CaSR (1) CDK (1) Collagen (1) COX (1) CRFR (3) Cytochrome P450 (1) Dopamine Receptor (3) Drug Derivative (2) Drug Intermediate (1) Drug Metabolite (2) E1/E2/E3 Enzyme (4) Elastase (1) Endogenous Metabolite (6) Endothelin Receptor (16) ERK (4) Estrogen Receptor/ERR (3) FGFR (2) G Protein-coupled Receptor Kinase (GRK) (2) Glutathione S-transferase (1) GSK-3 (1) Guanylate Cyclase (7) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) HSP (2) Integrin (1) Interleukin Related (2) Isotope-Labeled Compounds (8) Leukotriene Receptor (2) Lipoxygenase (1) LPL Receptor (3) Lysyl Oxidase (1) Macrophage migration inhibitory factor (MIF) (1) mGluR (1) Mitophagy (1) MMP (3) Monoamine Oxidase (2) mTOR (3) NADPH Oxidase (3) Neprilysin (2) NF-κB (5) P-glycoprotein (2) P2Y Receptor (1) p38 MAPK (6) Parasite (3) PDGFR (3) Phosphodiesterase (PDE) (16) PI3K (1) PKG (1) Potassium Channel (2) PPAR (2) Prostaglandin Receptor (14) PTEN (2) Reactive Oxygen Species (ROS) (1) Reference Standards (16) SARS-CoV (2) Sirtuin (2) Sodium Channel (1) SphK (2) STAT (4) Survivin (1) TGF-beta/Smad (3) TGF-β Receptor (15) TNF Receptor (3) TRP Channel (1) Tryptophan Hydroxylase (1)
By Research Areas:	Cancer (22) Cardiovascular Disease (111) Endocrinology (9) Infection (6) Inflammation/Immunology (29) Metabolic Disease (19) Neurological Disease (16)
Oligonucleotides:	Aptamers (1)

140

Inhibitors & Agonists

Screening-Bibliotheken

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-N0750

Monocrotaline Maximum Cited Publications 44 Publications Verification Crotaline	Others	Infection Metabolic Disease Cancer
Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid. Monocrotaline inhibits OCT-1 and OCT-2 with IC₅₀s of 36.8 µM and 1.8 mM, respectively. Monocrotaline has antitumor activity and is cytotoxic to hepatocellular carcinoma cells. Monocrotaline is used to induce a model of pulmonary hypertension in rodents. ^[2][6][8].

HY-14184

Macitentan 10+ Cited Publications ACT-064992	Endothelin Receptor Apoptosis	Cardiovascular Disease Endocrinology Cancer
Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .

HY-14779

Riociguat 15+ Cited Publications BAY 632521	Guanylate Cyclase	Cardiovascular Disease
Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.

HY-A0126A

Epoprostenol sodium 1 Publications Verification Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan	Endogenous Metabolite Apoptosis	Cardiovascular Disease
Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .

HY-P0012

Aviptadil 2 Publications Verification Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-11103

Sitaxsentan sodium 2 Publications Verification IPI 1040 sodium; TBC11251 sodium	Endothelin Receptor TGF-β Receptor	Cardiovascular Disease Metabolic Disease
Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC₅₀ of 1.4 nM and a K_i of 0.43 nM. Sitaxsentan sodium exhibits an IC₅₀ for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .

HY-12378

BQ-123 3 Publications Verification	Endothelin Receptor	Cardiovascular Disease
BQ-123 is a potent and selective endothelin A (ETA) receptor antagonist with an IC₅₀ of 7.3 nM and a K_i of 25 nM. BQ-123 inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension .

HY-148826

Rovunaptabin ARC 183; BC 007	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
Rovunaptabin (ARC 183) is an aptamer, a single-stranded DNA molecule composed of 15 deoxynucleotides. It acts as a broad-spectrum neutralizer of pathogenic G-protein-coupled receptor autoantibodies. Rovunaptabin can be used in research related to cardiomyopathy and pulmonary hypertension .

HY-10447

Terameprocol EM-1421	Survivin COX TNF Receptor Apoptosis	Infection Inflammation/Immunology Cancer
Terameprocol is an inhibitor targeting the Sp1 transcription factor, which can selectively inhibit the transcription of Sp1-dependent genes. Terameprocol exerts its effects by inhibiting Sp1-mediated gene transcription, such as reducing the expression of genes like CDC2, survivin and HMGB1, thereby arresting the cell cycle, inducing apoptosis, and suppressing the inflammatory response. Terameprocol exhibits anti-proliferative, pro-apoptotic, and anti-inflammatory activities and is currently mainly used in the research of diseases such as cancer and pulmonary arterial hypertension[1][2][3].

HY-109190

Seralutinib 2 Publications Verification GB002; PK10571	PDGFR c-Fms c-Kit	Cardiovascular Disease
Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC₅₀s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension .

HY-109163

Treprostinil palmitil INS-1009	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
Treprostinil palmitil is a long-acting inhaled pulmonary vasodilator prodrug of Treprostinil (HY-100441), formulated in a lipid nanoparticle (LNP). Treprostinil palmitil can inhibit pulmonary vascular remodeling induced by Su/Hx challenge in rats. Treprostinil palmitil can induce cough. Treprostinil palmitil demonstrates a sustained presence in the lungs with reduced systemic exposure and prolonged inhibition of hypoxia-induced pulmonary vasoconstriction in vivo. Treprostinil palmitil can be studied in research for pulmonary arterial hypertension and interstitial lung disease .

HY-13569A

Beraprost sodium TRK-100; ML 1129 sodium	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
Beraprost sodium (TRK-100), a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium (TRK-100) is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation . Beraprost sodium (TRK-100) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-154970A

BMPR2-IN-1 TFA	TGF-β Receptor GSK-3	Cardiovascular Disease Neurological Disease Cancer
BMPR2-IN-1 TFA is a selective BMPR2 inhibitor with a human BMPR2 IC₅₀ of 506 nM and a K_d of 83.5 nM. BMPR2-IN-1 TFA functions as an ATP mimetic, forming hydrogen bonds with the BMPR2 kinase domain backbone and hydrophobic interactions with specific residues, and demonstrates high selectivity for BMPR2 over other kinases.BMPR2-IN-1 TFA can be used for the researches of cancer, pulmonary arterial hypertension and Alzheimer’s disease .

HY-40136

cis-4-Hydroxy-L-proline	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .

HY-103080

CMF019	Apelin Receptor (APJ)	Cardiovascular Disease
CMF019 is an orally active, potent and small molecule agonist at Apelin receptor (APJ) with G protein bias. CMF019 binds to APJ with pKi values of 8.58, 8.49 and 8.71 for human, rat, and mouse, respectively. CMF019 mimics the beneficial cardiovascular actions of apelin in rodents . Apelin receptor (APJ) is a G protein-coupled receptor (GPCR) activated by the endogenous peptide apelin. CMF019 is promising for research of chronic diseases, such as, pulmonary arterial hypertension .

HY-101124

Rodatristat ethyl KAR5585	Tryptophan Hydroxylase 5-HT Receptor	Cardiovascular Disease
Rodatristat ethyl (KAR5585) is a first-in-class oral tryptophan hydroxylase 1 (TPH1) Inhibitor with nanomolar in vitro potency. Rodatristat ethyl reduces the level of 5-HT and significantly reduces pulmonary arterial hypertension (PAH) .

HY-170419

APJ receptor agonist 10	Apelin Receptor (APJ)	Cardiovascular Disease
APJ receptor agonist 10 is an agonist of the APJ Receptor. APJ receptor agonist 10 can be used for research on pulmonary arterial hypertension .

HY-150793

SY-LB-57	TGF-β Receptor	Cardiovascular Disease Neurological Disease
SY-LB-57 is a highly potent bone morphogenetic protein (BMP) receptor signaling agonist. SY-LB-57 can be used in studies of diseases such as fractures and pulmonary arterial hypertension .

HY-129851

NTP42	Prostaglandin Receptor	Cardiovascular Disease
NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC₅₀ of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca ²⁺] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .

HY-11095

NPS 2390	mGluR CaSR PI3K Akt mTOR Autophagy Apoptosis Bcl-2 Family Caspase	Cardiovascular Disease Neurological Disease
NPS 2390 is an allosteric antagonist of calcium-sensing receptor (CaSR) and mGluR1/5. NPS 2390 inhibits the PI3K/Akt/mTOR signaling pathway, reduces hypoxia-induced intracellular calcium elevation, decreases the expression of autophagy (autophagy) proteins, regulates the expression of phenotypic marker proteins, and inhibits the proliferation of pulmonary artery smooth muscle cells. NPS 2390 attenuates the endogenous apoptosis (apoptosis) pathway, increases the expression level of Bcl-2, downregulates the expression levels of Bax, cytochrome c and caspase-3, alleviates cerebral edema and improves neurological function in rat models. NPS 2390 can be used in studies related to hypoxic pulmonary hypertension, traumatic brain injury, stroke and pain .

HY-P0012A

Aviptadil acetate 2 Publications Verification Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-128932

Cefminox sodium 1 Publications Verification MT-141	Antibiotic Bacterial PPAR Prostaglandin Receptor PTEN Akt mTOR	Infection Cardiovascular Disease Endocrinology
Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model .

HY-90009S

Tadalafil-d3 IC-351-d₃	Phosphodiesterase (PDE)	Cardiovascular Disease
Tadalafil-d₃ is the deuterium labeled Nortadalafil. Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension.

HY-14184S

Macitentan-d4 ACT-064992-d₄	Isotope-Labeled Compounds Endothelin Receptor Apoptosis	Cardiovascular Disease
Macitentan-d₄ is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .

HY-14184R

Macitentan (Standard) ACT-064992 (Standard)	Reference Standards Endothelin Receptor Apoptosis	Cardiovascular Disease Endocrinology Cancer
Macitentan (Standard) is the analytical standard of Macitentan. This product is intended for research and analytical applications. Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .

HY-149316

Smurf1-IN-1	E1/E2/E3 Enzyme	Cardiovascular Disease
Smurf1-IN-1 is an orally active and selective inhibitor of specific E3 ubiquitin protein ligase 1 (SMURF1) with an IC₅₀ of 92 nM. Smurf1-IN-1 has significant efficacy in rats model of pulmonary hypertension .

HY-130581

Lipid X	Bacterial	Cardiovascular Disease Inflammation/Immunology
Lipid X is a 2,3-diacylglucosamine-1-phosphate that serves as the monosaccharide precursor of lipid A, possessing both LPS antagonist and weak agonist activities. Lipid X exerts protective effects by inhibiting tumor necrosis factor production, monocyte procoagulant activity, and neutrophil priming. Lipid X may induce transient pulmonary hypertension, neutropenia, and mild pyrogenic effects in laboratory animals. Lipid X has low toxicity and no in vitro antibacterial activity, but it significantly reduces mortality following Gram-negative bacterial infection and endotoxin exposure. Lipid X tends to accumulate in liver tissue, binds to circulating cellular components, and can be converted to lipid Y through transesterification. Lipid X can be used in research on Gram-negative bacterial sepsis, endotoxemia, and associated pulmonary hypertension .

HY-N9279

Dehydromonocrotaline Monocrotaline pyrrole; MCTP; 3,8-Didehydromonocrotaline	Endogenous Metabolite	Cardiovascular Disease Cancer
Dehydromonocrotaline is a mitochondrial respiratory chain complex I NADH oxidase inhibitor, with a IC₅₀ of 62.06 μM and a K_i of 8.1 μM in rats. Dehydromonocrotaline exerts non-competitive inhibitory effects by modifying cysteine thiol groups on complex I, and does not bind to the NADH-binding site. Dehydromonocrotaline dissipates mitochondrial membrane potential and reduces ATP levels. Dehydromonocrotaline can be used in studies related to hepatotoxicity, pulmonary hypertension and liver tumors .

HY-128593

TPN171	Phosphodiesterase (PDE)	Cardiovascular Disease
TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC₅₀ of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH) .

HY-118010A

(+)-Norfenfluramine hydrochloride d-Norfenfluramine hydrochloride	5-HT Receptor	Cardiovascular Disease
(+)-Norfenfluramine hydrochloride, a major hepatic metabolite of (+)-fenfluramine, is a selective 5-HT_2B receptor agonist (K_i: 11.2 nM). (+)-Norfenfluramine hydrochloride potently stimulates the hydrolysis of inositol phosphates and increases intracellular Ca ²⁺. (+)-Norfenfluramine hydrochloride can be used for the research of primary pulmonary hypertension and valvular heart disease .

HY-W131725

(+)-Norfenfluramine d-Norfenfluramine	5-HT Receptor	Cardiovascular Disease
(+)-Norfenfluramine a major hepatic metabolite of (+)-fenfluramine, is a selective 5-HT_2B receptor agonist (K_i: 11.2 nM). (+)-Norfenfluramine potently stimulates the hydrolysis of inositol phosphates and increases intracellular Ca ²⁺. (+)-Norfenfluramine can be used for the research of primary pulmonary hypertension and valvular heart disease .

HY-162888

WQ-C-401	PDGFR ERK	Cardiovascular Disease
WQ-C-401 is an orally active platelet-derived growth factor receptor (PDGFR) inhibitor. WQ-C-401 inhibits cell proliferation by blocking PDGFR autophosphorylation in a concentration-dependent manner, with EC₅₀ values of 3.5 nM for PDGFRα Y849 and 5.8 nM for PDGFRβ Y1021. Additionally, WQ-C-401 can inhibit PASMCs proliferation and migration by blocking PDGF-BB-induced ERK1/2 phosphorylation, reducing collagen I synthesis, and increasing α-SMA expression, thereby preventing pulmonary vascular remodeling. WQ-C-401 holds promise for research in the field of pulmonary arterial hypertension .

HY-76520

Sitaxsentan IPI 1040; TBC-11251	Endothelin Receptor TGF-β Receptor	Cardiovascular Disease Metabolic Disease
Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC₅₀ of 1.4 nM and a K_i of 0.43 nM. Sitaxsentan exhibits an IC₅₀ for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .

HY-167906

Lunamarine	Bacterial Phosphodiesterase (PDE)	Metabolic Disease
Lunamarine is a inhibitor of PDE5 with BBB permeability. Lunamarine can be used in the reseach of Pulmonary Arterial Hypertension (PAH) and Erectile Dysfunction (ED) .

HY-154970

BMPR2-IN-1	TGF-β Receptor	Cancer
BMPR2-IN-1 (Compound 8a) is a BMPR2 inhibitor with an IC₅₀ of 506 nM and a K_D of 83.5 nM. BMPR2-IN-1 can be used for research of pulmonary arterial hypertension, Alzheimer’s disease and cancer .

HY-105408A

Fandosentan potassium	Endothelin Receptor Cytochrome P450	Cardiovascular Disease
Fandosentan potassium is a potent endothelin A receptor (ET_AR) antagonist. Fandosentan potassium inhibits CYP2C9 and CYP3A4 activities with IC₅₀ values of 39.6 and 21.6 μM, respectively. Fandosentan potassium reverses the hypoxic pulmonary vasoconstriction in the perinatal lamb. Fandosentan potassium can be used for pulmonary hypertension research ^[1][2].

HY-123744

PD-156707	Endothelin Receptor	Cardiovascular Disease Neurological Disease
PD-156707 is an orally active, nonpeptide and selective Endothelin-A receptor antagonist. PD-156707 binds to human ET-A and ET-B receptors with K_i values of 0.17 nM and 133.8 nM, respectively. PD-156707 shows reversal of established chronic hypoxic pulmonary hypertension in rats. PD-156707 can be used for the study of diseases associated with abnormal ET-A receptor activation, particularly pulmonary hypertension, stroke, and heart failure .

HY-P3227

Cyclo(Ala-Arg-Gly-Asp-Mamb) XJ735	Integrin	Inflammation/Immunology
Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension research .

HY-172234

PF-06842874	CDK	Cardiovascular Disease Cancer
PF-06842874 is a CDK4/Cyclin D1 and CDK6/Cyclin D3 inhibitor (K_i values are 62 and 130 nM, respectively). PF-06842874 can be used in the research of pulmonary arterial hypertension and cancer .

HY-148670

Pulmonary arterial hypertension agent-1	Drug Intermediate Prostaglandin Receptor	Cardiovascular Disease
Pulmonary arterial hypertension agent-1 (example 15) is a pulmonary arterial hypertension agent . Pulmonary arterial hypertension agent-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-177948

GRK2 degrader-1	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
GRK2 degrader-1 (compound 1) is a potent and orally active GRK2 degrader. GRK2 degrader-1 degrades GRK2 via the ubiquitin-proteasome pathway. GRK2 degrader-1 inhibits right ventricular remodeling and elevation of pulmonary artery pressure in a pulmonary artery hypertension (PAH) mouse model. GRK2 degrader-1 can be used for PAH research .

HY-13569AR

Beraprost sodium (Standard) TRK-100 (Standard); ML 1129 sodium (Standard)	Reference Standards Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
Beraprost (sodium) (Standard) is the analytical standard of Beraprost (sodium). This product is intended for research and analytical applications. Beraprost sodium, a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation . Beraprost (sodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-168985

Mirivadelgat	Aldehyde Dehydrogenase (ALDH)	Cancer
Mirivadelgat is an activator of aldehyde dehydrogenase 2 activator. Mirivadelgat is promising for research of interstitial lung disease-pulmonary hypertension and cancers .

HY-14184A

Macitentan n-butyl analogue	Endothelin Receptor	Cardiovascular Disease Endocrinology
Macitentan n-butyl analogue is a n-butyl analogue of Macitentan. Macitentan is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

HY-165587

BM-573	Prostaglandin Receptor	Cardiovascular Disease
BM-573 is an orally active dual thromboxane A₂ (TXA₂) modulator with an IC₅₀ of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA₂ analogues). BM-573 completely blocks the generation of TXB₂ (the stable metabolite of TXA₂) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED₅₀ = 4.2 μM), but has no effect on contractions caused by PGE₂, PGF₂α, or PGI₂. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock .

HY-172094

AMPK-IN-6	AMPK Apoptosis Autophagy	Cardiovascular Disease
AMPK-IN-6 (compound 13a) is potent AMPK inhibitor with an IC₅₀ value of 0.093 µM. AMPK-IN-6 induces apoptosis and inhibits autophagy. AMPK-IN-6 shows antiproliferative activity. AMPK-IN-6 has the potential for the research of pulmonary arterial hypertension .

HY-117109R

Amino Tadalafil (Standard)	Reference Standards Drug Derivative	Others
Amino Tadalafil (Standard) is the analytical standard of Amino Tadalafil. This product is intended for research and analytical applications. Amino Tadalafil is a structural analogue of Tadalafil (HY-90009A). Tadalafil is a potent inhibitor of PDE5 with applications in several conditions, including erectile dysfunction, pulmonary arterial hypertension, and lower urinary tract dysfunction .

HY-112704

PDE5-IN-2	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-2 is a potent, highly selective, and orally active PDE5 inhibitor, with an IC₅₀ of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC₅₀s of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arterial hypertension activity .

HY-124051

BAY-8040	Elastase	Cardiovascular Disease Inflammation/Immunology
BAY-8040 is a pyrimidopyridazine derivative which has inhibitory activity against human neutrophil elastase (HNE). BAY-8040 decreases cardiac remodeling and ameliorates cardiac function in a Monocrotaline (HY-N0750)-induced rat model for pulmonary arterial hypertension. BAY-8040 is promising for research of inflammatory pathologies and cardiopulmonary pathologies .

HY-106861

NIP-121	Potassium Channel	Cardiovascular Disease
NIP-121 is a new type of potassium channel opener. NIP-121 significantly reduces mean pulmonary artery pressure and total pulmonary resistance through vasodilation. NIP-121 can be used for research on pulmonary arterial hypertension .

Art. -Nr.	Produktname

HY-L125

Anti-Pulmonary Fibrosis Compound Library

2,653 compounds

Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 2,653 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.

Art. -Nr.	Produktname	Target	Research Area

HY-P0012

Aviptadil 2 Publications Verification Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-12378

BQ-123 3 Publications Verification	Endothelin Receptor	Cardiovascular Disease
BQ-123 is a potent and selective endothelin A (ETA) receptor antagonist with an IC₅₀ of 7.3 nM and a K_i of 25 nM. BQ-123 inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension .

HY-P1752

Urocortin II, human	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human is a selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor. Urocortin II, human has an effect of promoting satiet and neuroprotective effect. Urocortin II, human also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P0012A

Aviptadil acetate 2 Publications Verification Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P1435

NoxA1ds	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds can be used in the study of hypertension, atherosclerosis and tumors .

HY-P1752B

Urocortin II, human acetate	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human acetate is a selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor. Urocortin II, human acetate has an effect of promoting satiet and neuroprotective effect. Urocortin II, human acetate also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human acetate can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human acetate can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human acetate can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P3227

Cyclo(Ala-Arg-Gly-Asp-Mamb) XJ735	Integrin	Inflammation/Immunology
Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension research .

HY-P1435A

NoxA1ds TFA	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds TFA is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds TFA inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds TFA can be used in the study of hypertension, atherosclerosis and tumors .

HY-P1752A

Urocortin II, human TFA	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human TFA is a selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor. Urocortin II, human TFA has an effect of promoting satiet and neuroprotective effect. Urocortin II, human TFA also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human TFA can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human TFA can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human TFA can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

Art. -Nr.	Produktname	Target	Research Area	Image

HY-P99590

Sotatercept 2 Publications Verification ACE-011; MK-7962	TGF-β Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .

HY-P992008

PF-07868489	TGF-β Receptor	Cardiovascular Disease
PF-07868489 is a recombinant monoclonal antibody targeting GDF2/BMP-9. PF-07868489 can be used for the research of pulmonary arterial hypertension (PAH). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991758

Anti-Mouse PDGFRα Antibody (APA5)	PDGFR	Cardiovascular Disease
Anti-Mouse PDGFRα Antibody (APA5) reacts with mouse PDGFRα. Anti-Mouse PDGFRα Antibody (APA5) can be used to block PDGFRα in vitro and in vivo. Anti-Mouse PDGFRα Antibody (APA5) can be used for the study of pulmonary hypertension. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .

Art. -Nr.	Produktname	Category	Target	Chemical Structure

HY-N0750

Monocrotaline Maximum Cited Publications 44 Publications Verification Crotaline	Structural Classification Alkaloids Pyrrole Alkaloids Classification of Application Fields Leguminosae Crotalaria pallida Ait. Plants Disease Research Fields Cancer	Others
Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid. Monocrotaline inhibits OCT-1 and OCT-2 with IC₅₀s of 36.8 µM and 1.8 mM, respectively. Monocrotaline has antitumor activity and is cytotoxic to hepatocellular carcinoma cells. Monocrotaline is used to induce a model of pulmonary hypertension in rodents. ^[2][6][8].

HY-111557

YM-254890 15+ Cited Publications	Cardiovascular Disease Natürliche Produkte Microorganisms Classification of Application Fields Disease Research Fields Source Classification	P2Y Receptor
YM-254890 is a selective G_αq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the P2Y₁ signal transduction pathway, with an IC₅₀ value below 0.6 μM .

HY-A0126A

Epoprostenol sodium 1 Publications Verification Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Apoptosis
Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .

HY-N0485

Liensinine Diperchlorate 15+ Cited Publications	Cardiovascular Disease Alkaloids Piperidine Alkaloids Classification of Application Fields Phenols Polyphenols Nelumbo nucifera Gaertn. Plants Disease Research Fields Nymphaeaceae Source Classification	Autophagy Mitophagy
Liensinine Diperchlorate is a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn. Liensinine Diperchlorate inhibits late-stage autophagy/mitophagy through blocking autophagosome-lysosome fusion. Liensinine Diperchlorate has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc .

HY-40136

cis-4-Hydroxy-L-proline	Microorganisms Classification of Application Fields Santalum album Linn. Ketones, Aldehydes, Acids Metabolic Disease Plants Endogenous metabolite Disease Research Fields Source Classification Santalaceae	Endogenous Metabolite
cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .

HY-N9279

Dehydromonocrotaline Monocrotaline pyrrole; MCTP; 3,8-Didehydromonocrotaline	Pyrrolizidine Alkaloids Structural Classification Alkaloids Endogenous metabolite Source Classification	Endogenous Metabolite
Dehydromonocrotaline is a mitochondrial respiratory chain complex I NADH oxidase inhibitor, with a IC₅₀ of 62.06 μM and a K_i of 8.1 μM in rats. Dehydromonocrotaline exerts non-competitive inhibitory effects by modifying cysteine thiol groups on complex I, and does not bind to the NADH-binding site. Dehydromonocrotaline dissipates mitochondrial membrane potential and reduces ATP levels. Dehydromonocrotaline can be used in studies related to hepatotoxicity, pulmonary hypertension and liver tumors .

HY-N16469

Ruscin Ruscoponticoside D; Neoruscine	Structural Classification Liliaceae Plants Ruscus aculeata Linn. Steroids Source Classification	Others
Ruscin (Ruscoponticoside D; Neoruscine) is steroidal saponin found in Butcher’s Broom. Ruscin has multiple bioactivities and possesses a variety of pharmacological activities, including anti-inflammatory properties, platelet aggregation inhibition, pulmonary hypertension lowering properties, acute lung injury alleviation .

HY-N0750R

Monocrotaline (Standard) Crotaline (Standard)	Structural Classification Alkaloids Pyrrole Alkaloids Leguminosae Crotalaria pallida Ait. Plants	Reference Standards Others
Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid. Monocrotaline inhibits OCT-1 and OCT-2 with IC50s of 36.8 µM and 1.8 mM, respectively. Monocrotaline has antitumor activity and is cytotoxic to hepatocellular carcinoma cells. Monocrotaline is used to induce a model of pulmonary hypertension in rodents. .

HY-40136R

cis-4-Hydroxy-L-proline (Standard)	Structural Classification Microorganisms Santalum album Linn. Ketones, Aldehydes, Acids Plants Endogenous metabolite Source Classification Santalaceae	Reference Standards Endogenous Metabolite
cis-4-Hydroxy-L-proline (Standard) is the analytical standard of cis-4-Hydroxy-L-proline (HY-40136). This product is intended for research and analytical applications. cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .

Art. -Nr.	Produktname	Chemical Structure

HY-90009S

Tadalafil-d3
Tadalafil-d₃ is the deuterium labeled Nortadalafil. Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension.

HY-14184S

Macitentan-d4
Macitentan-d₄ is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .

HY-40136S

cis-4-Hydroxy-L-proline-d3

cis-4-Hydroxy-L-proline-d₃ is the deuterium labeled cis-4-Hydroxy-L-proline (HY-40136). cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .

HY-14779S3

Riociguat-d3
Riociguat-d₃ (BAY 632521-d₃) is deuterium labeled Riociguat. Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.

HY-14779S

Riociguat-13C,d6
Riociguat- ¹³C,d₆ is the ¹³C and deuterium labeled Riociguat (HY-14779). Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.

HY-76520S

Sitaxsentan-13C6

Sitaxsentan- ¹³C₆ (IPI 1040- ¹³C₆) is ¹³C labeled Sitaxsentan (HY-76520). Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC₅₀ of 1.4 nM and a K_i of 0.43 nM. Sitaxsentan exhibits an IC₅₀ for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .

HY-167906S

Hexadecyl 2-((4-Nitrophenyl)thio)acetate-13C2
Hexadecyl 2-((4-Nitrophenyl)thio)acetate- ¹³C₂ is the ¹³C-labeled Lunamarine (HY-167906). Lunamarine is a inhibitor of PDE5 with BBB permeability. Lunamarine can be used in the reseach of Pulmonary Arterial Hypertension (PAH) and Erectile Dysfunction (ED) .

HY-B0130S1

Perindopril-d5

Perindopril-d₅ (S-9490-d₅) is deuterium labeled Perindopril. Perindopril (S-9490) is an orally available, long-acting angiotensin-converting enzyme (ACE) inhibitor. Perindopril inhibits inflammatory cell influx and intimal thickening, preserving elastin on the inside of the aorta. Perindopril effectively inhibits experimental abdominal aortic aneurysm (AAA) formation in a rat model and reduces pulmonary vasoconstriction in rats with pulmonary hypertension .

HY-132184S

5,6-Epoxyeicosatrienoic acid-d11

5,6-Epoxyeicosatrienoic acid-d₁₁ (5,6-EET-d₁₁) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid is one of the four major epoxyeicosatrienoic acid (EET) isomers metabolized from Arachidonic acid (HY-109590). 5,6-Epoxyeicosatrienoic acid induces peripheral vasodilation and lowers blood pressure by inhibiting T-type calcium channels (Cav3.2: IC₅₀ = 0.54 μM). 5,6-Epoxyeicosatrienoic acid causes vasoconstriction in hypoxic pulmonary blood vessels via activating Rho kinase in a membrane depolarization-dependent manner. 5,6-Epoxyeicosatrienoic acid induces mechanical pain by activating TRPA1. 5,6-Epoxyeicosatrienoic acid can be used in studies related to hypoxic pulmonary vasoconstriction, mechanical hyperalgesia and hypertension.

Art. -Nr.	Produktname		Classification